港股早評:恆指微幅低開0.1% 科技股普跌 醫藥股強勢
格隆匯8月16日丨港股三大指數低開,恆指跌0.1%報26365點,國指跌0.03%9374點報,恆生科技指數跌0.41%6562點報。盤面上,生物醫藥股強勢,麗珠醫藥高開逾3%,金斯瑞生物科技漲超3%;銀行股、電力股、物管股、物管股、建材水泥股、保險股、銀行股普遍上漲,招商銀行漲2%;大型科技股普跌,百度低開逾3%,美團、京東、騰訊均跌超1%;教育股繼續下跌,汽車股、濠賭股普跌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.